CHAPEL HILL, N.C.– Areteia Therapeutics announces two key leadership appointments: Dr. Eric Bradford M.D. as Chief Medical Officer and Robin Walker J.D. as Chief Legal Officer and Corporate Secretary. These appointments report to Jorge Bartolome, CEO of Areteia Therapeutics and are effective immediately.
Eric joins Areteia after a 20+ year career in biopharma, working on early-stage research, clinical development, medical affairs, life cycle management and commercialization. He has extensive experience in asthma, respiratory diseases, as well as other therapeutic areas, spanning 18 years at GSK. During this time, he oversaw numerous global studies, and provided medical affairs and development leadership for the anti-IL5 mAB programs targeting severe asthma. Eric joins the executive leadership team with responsibility for overseeing all medical functions within the company.
Robin joins Areteia with 20+ years of legal experience across a variety of disciplines, including compliance, corporate governance, regulatory, risk management, M&A, alliance management and intellectual property for public and private companies. Most recently, she was the Chief Legal and Compliance Officer and Corporate Secretary at Goldfinch Bio and Stoke Therapeutics. Prior to this, Robin worked for 8 years at Biogen where she was Research and Development Counsel as well as Associate General Counsel. She joins the executive leadership team, responsible for all legal and compliance matters for the company.
“I am thrilled to expand and further strengthen our team with these two important leadership appointments,” said Jorge Bartolome, CEO of Areteia Therapeutics. He added “they both bring years of highly relevant experience and will play an essential role in fulfilling our mission to put asthma patients in better control of their disease and lives.”
